Minocycline HCl Microspheres — Competitive Intelligence Brief

Minocycline HCl Microspheres (Minocycline HCl Microspheres) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Tetracycline antibiotic. Area: Dentistry / Periodontics.

marketed Tetracycline antibiotic Bacterial 30S ribosome Dentistry / Periodontics Small molecule

Target snapshot

Minocycline HCl Microspheres (Minocycline HCl Microspheres) — OraPharma. Minocycline HCl microspheres deliver the antibiotic minocycline directly into periodontal pockets to inhibit bacterial growth and reduce inflammation in periodontal disease.

Comparator set (6 drugs)

Drug	Generic	Sponsor	Phase	Class	Target	Approval / PDUFA
Minocycline HCl Microspheres TARGET	Minocycline HCl Microspheres	OraPharma	marketed	Tetracycline antibiotic	Bacterial 30S ribosome
Dexamethasone, tobramycin, netilimicin	Dexamethasone, tobramycin, netilimicin	Kasr El Aini Hospital	marketed	Corticosteroid + aminoglycoside antibiotics	Glucocorticoid receptor (dexamethasone); bacterial 30S ribosome (tobramycin, netilimicin)
Minocycline,Metronidazole	Minocycline,Metronidazole	Shanghai Jiao Tong University School of Medicine	marketed	Combination antibiotic	Bacterial 30S ribosome (minocycline); microbial DNA/RNA (metronidazole)
Tetracycline,Metronidazole	Tetracycline,Metronidazole	Shanghai Jiao Tong University School of Medicine	marketed	Antibiotic combination	Bacterial 30S ribosome (tetracycline); anaerobic DNA/RNA (metronidazole)
Gentamicin + narrow spectrum betalactam	Gentamicin + narrow spectrum betalactam	University Hospital, Akershus	marketed	Aminoglycoside + Beta-lactam antibiotic combination	Bacterial 30S ribosome (gentamicin); Penicillin-binding proteins (beta-lactam)
Tetracycline, Metronidazole, Bismuth subcitrate	Tetracycline, Metronidazole, Bismuth subcitrate	Mackay Memorial Hospital	marketed	Antibiotic combination therapy	Bacterial 30S ribosome (tetracycline), bacterial DNA (metronidazole), bacterial cell wall (bismuth)
Vancomycin and Gentamicin	Vancomycin and Gentamicin	Memorial Sloan Kettering Cancer Center	marketed	Antibiotic combination (glycopeptide + aminoglycoside)	Bacterial cell wall (vancomycin) and bacterial 30S ribosome (gentamicin)

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Tetracycline antibiotic class)

1. OraPharma · 2 drugs in this class
2. Vyne Therapeutics Inc. · 2 drugs in this class
3. Beijing Tiantan Hospital · 1 drug in this class
4. Clinica Universidad de Navarra, Universidad de Navarra · 1 drug in this class
5. Darier · 1 drug in this class
6. Edward Lain, MD · 1 drug in this class
7. Generic (originally Pfizer) · 1 drug in this class
8. Galderma R&D · 1 drug in this class
9. Johns Hopkins University · 1 drug in this class
10. Chinese University of Hong Kong · 1 drug in this class